APOA1 and atherosclerosis: Beyond apabetalone, ApoAI overexpression was studied long-term in a mouse model, resulting in a sixfold reduction in the formation of atherosclerotic plaques, showing significant promise for the reduction of atherosclerosis via ApoAI increase [47].